新鋭醫藥(06108.HK)年度淨虧擴大至6970萬港元
格隆匯 4 月 1日丨新鋭醫藥(06108.HK)發佈公吿,截至2020年12月31日止年度,集團錄得收益約1.332億港元,同比增加約12.3%;毛利約為1090萬港元,同比減少約26.8%;公司擁有人應占淨虧損約為6970萬港元,同比增加約58.0%;基本每股虧損4.17港仙。
公吿表示,本年度的總收益約同比增加約12.3%。醫藥產品分銷及貿易的收益增加主要由於2019年臨時暫停生產及出售該產品(1.0g)後,該產品(1.0g)已於2019年9月起恢復生產及出售。儘管該產品(1.0g)於本年度的銷售表現有所改善,惟此分部業務因年內爆發Covid-19疫情,令集團的貿易活動及業務營運放緩而受到影響,加上年內中國部分地區新近推行藥品集中採購文件,使該產品(1.0g)的平均售價下跌。本年度集團提供營銷及推廣服務所產生的收益與2019年相比保持穩定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.